O
HRTX icon

OrbiMed’s Heron Therapeutics HRTX Stock Holding History

OrbiMed’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,816,940
Closed -$7.85M – 141
2026
Q1 		$7.85M Buy
+9,816,940
New +$11.4M 0.16% 84
2024
Q3 		– Sell
-6,512,866
Closed -$22.8M – 126
2024
Q2 		$22.8M Sell
6,512,866
-3,598,684
-36% -$11.1M 0.45% 57
2024
Q1 		$28M Buy
10,111,550
+4,182,959
+71% +$10.5M 0.51% 53
2023
Q4 		$10.1M Buy
5,928,591
+5,125,891
+639% +$5.64M 0.2% 77
2023
Q3 		$827K Hold
802,700
– – 0.02% 121
2023
Q2 		$931K Hold
802,700
– – 0.02% 121
2023
Q1 		$1.21M Buy
+802,700
New +$2.01M 0.02% 115
2022
Q4 		– Sell
-1,123,000
Closed -$4.74M – 122
2022
Q3 		$4.74M Buy
+1,123,000
New +$4.39M 0.09% 106
2021
Q1 		– Sell
-1,191,846
Closed -$25.2M – 170
2020
Q4 		$25.2M Hold
1,191,846
– – 0.22% 91
2020
Q3 		$17.7M Buy
1,191,846
+531,426
+80% +$8.29M 0.22% 89
2020
Q2 		$9.71M Buy
660,420
+123,000
+23% +$2.02M 0.14% 102
2020
Q1 		$6.31M Buy
+537,420
New +$10.1M 0.11% 97
2019
Q2 		– Sell
-1,069,000
Closed -$26.1M – 132
2019
Q1 		$26.1M Sell
1,069,000
-331,300
-24% -$8.67M 0.4% 61
2018
Q4 		$36.3M Sell
1,400,300
-114,200
-8% -$3.14M 0.67% 47
2018
Q3 		$47.9M Buy
1,514,500
+199,400
+15% +$7.43M 0.58% 55
2018
Q2 		$51.1M Buy
1,315,100
+175,300
+15% +$5.58M 0.61% 50
2018
Q1 		$31.5M Buy
1,139,800
+489,800
+75% +$11.1M 0.39% 66
2017
Q4 		$11.8M Hold
650,000
– – 0.15% 101
2017
Q3 		$10.5M Hold
650,000
– – 0.1% 106
2017
Q2 		$9M Hold
650,000
– – 0.09% 99
2017
Q1 		$9.75M Buy
+650,000
New +$9M 0.11% 98

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

OrbiMed's HRTX Position: Q2 2026 in Review

OrbiMed sold out of Heron Therapeutics (HRTX) in Q2 2026, closing a stake of 9,816,940 shares — an estimated $7.85M sold.

OrbiMed first reported a position in HRTX in Q1 2017 and held it in 21 quarters. The position peaked at $51.1M in Q2 2018. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • OrbiMed reported no remaining Heron Therapeutics position as of Q2 2026 after selling out during the quarter.
  • OrbiMed sold 9,816,940 Heron Therapeutics shares in Q2 2026, an estimated $7.85M.
  • OrbiMed first reported a position in Heron Therapeutics in Q1 2017 and held it in 21 quarters.
  • OrbiMed's Heron Therapeutics position peaked at $51.1M in Q2 2018.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.